You are now leaving the Grünenthal website. You will be re-directed to an external website. Grünenthal accepts no responsibility for the content of other websites.
Grünenthal’s focus on patients is at the core of our responsibility approach. We concentrate our efforts on the key areas of patient safety, product quality, improving patients’ quality of life through innovative medicines, access to healthcare and safe pain management through the responsible use of opioids.
Rigorous testing, quality control, and regulatory compliance ensure the safety, reliable availability, efficacy and quality of pharmaceutical products. This protects patients, helps improve their health and fosters trust.
While any medicine may cause side effects, Grünenthal’s priority is to ensure that the therapeutic benefits of the medicine outweigh the risks.
Patients should receive appropriate pain management after carefully weighing the benefits and risks of the available options.
With our Change Pain initiative, we educate healthcare professionals in pain management – while also educating healthcare professionals and patients on pain conditions. The goal is to build up knowledge on the responsible use of pain medicine to reduce risks related to its misuse.
Our research and development aims to create innovative medicines to improve the quality of life for patients experiencing chronic or acute pain and adjacent conditions.
Chronic pain continues to leave many patients without adequate treatment options. At Grünenthal, we focus on developing new therapies that offer meaningful benefits for people living with pain, while carefully considering safety, tolerability and long-term use.
By bringing together human data, digital tools and advanced analytics, we gain deeper insights into patients’ experiences and can design more targeted research and development initiatives.
Across all projects, one principle applies: innovation must be developed responsibly, with patient safety and ethical conduct guiding every decision.
Beyond our own pipeline, we invest in the future of pain science and awareness by supporting researchers who pursue innovative pain research and education.
Through the EFIC-Grünenthal-Grant (E-G-G), Grünenthal supports young scientists early in their career in carrying out innovative clinical pain research with up to € 110,000 provided every two years.
Grünenthal is also one of the main sponsors of the Societal Impact of Pain (SIP) platform, a multi-stakeholder partnership aiming to raise awareness of pain and encourage changes to pain policies.
Access to effective healthcare remains deeply unequal. As a manufacturer of active pharmaceutical ingredients and pain medicines, Grünenthal plays a direct role in closing that gap. Our goal is straightforward: balancing economic sustainability with social impact, taking step-by-step action to make sure our medicines reach the patients who need them.
We build on a proven track record of drug product donations. Looking ahead, Grünenthal aims to launch three new initiatives supporting patients in low- and middle-income countries by 2030, ensuring measurable, long-term impact.
The Grünenthal Foundation for Palliative Care was set up in 1998 to promote science and research in this field and to support the care of people with severe or terminal diseases.
The Foundation facilitated the creation of the Department of Palliative Medicine at the Aachen University Hospital in 2003 - the first of its kind in Germany.
In Peru, the Foundation supported the creation of the country’s first master’s degree in Palliative Medicine and Pain Management at the Universidad Nacional Mayor de San Marcos.
Launched in 2018, the programme has since trained hundreds of physicians and established an important academic foundation for palliative care in the country.